RT Journal Article
SR Electronic
T1 A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3303
OP 3310
VO 24
IS 5C
A1 TORU KANEKO
A1 SHIGENORI GOTO
A1 YOSHIAKI KUSHIMA
A1 YOJU MIYAMOTO
A1 MASAZUMI ERIGUCHI
A1 MIE NIEDA
A1 KOJI EGAWA
YR 2004
UL http://ar.iiarjournals.org/content/24/5C/3303.abstract
AB Background: Immunocell therapy has been applied to patients with refractory cancer in clinical trials or as an unconventional cancer therapy, however the efficacy is still limited. To improve this efficacy, a combination therapy may be beneficial. Molecularly-targeted therapy acts directly on neoplasm cells to suppress their growth without causing myelosuppression. Case Report: Recently, we encountered three patients treated by immunocell therapy with imatinib mesylate (Glivec®). One patient was diagnosed as having Philadelphia chromosome (Ph) (+) acute lymphoblastic leukemia (ALL) and had a relapse-free survival of more than 24 months. The other two were diagnosed as having GIST; a partial response was observed in one which lasted more than 21 months, while the other's disease has been stabilized for more than 25 months. No side-effects were observed, other than those mentioned in the directions for the use of imatinib. Conclusion: Immunocell therapy may have a potent therapeutic effect when used in combination with molecularly-targeted therapy, which has few side-effects.